ING Groep NV Has $63.40 Million Holdings in Abbott Laboratories $ABT

ING Groep NV grew its stake in Abbott Laboratories (NYSE:ABT) by 330.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 473,378 shares of the healthcare product maker’s stock after purchasing an additional 363,503 shares during the period. ING Groep NV’s holdings in Abbott Laboratories were worth $63,404,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the stock. Vanguard Group Inc. grew its position in Abbott Laboratories by 1.8% during the second quarter. Vanguard Group Inc. now owns 172,800,851 shares of the healthcare product maker’s stock worth $23,502,644,000 after buying an additional 2,977,715 shares in the last quarter. State Street Corp grew its holdings in shares of Abbott Laboratories by 0.9% during the 2nd quarter. State Street Corp now owns 78,354,270 shares of the healthcare product maker’s stock worth $10,656,964,000 after purchasing an additional 689,517 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Abbott Laboratories by 3.8% during the second quarter. Geode Capital Management LLC now owns 38,293,067 shares of the healthcare product maker’s stock valued at $5,184,589,000 after purchasing an additional 1,390,554 shares during the period. Norges Bank acquired a new position in shares of Abbott Laboratories in the second quarter valued at $3,026,180,000. Finally, Massachusetts Financial Services Co. MA lifted its position in Abbott Laboratories by 5.8% in the third quarter. Massachusetts Financial Services Co. MA now owns 15,096,907 shares of the healthcare product maker’s stock worth $2,022,080,000 after purchasing an additional 821,325 shares during the period. Institutional investors and hedge funds own 75.18% of the company’s stock.

Insider Transactions at Abbott Laboratories

In related news, Director Daniel J. Starks acquired 10,000 shares of the firm’s stock in a transaction on Wednesday, February 4th. The shares were purchased at an average price of $108.73 per share, with a total value of $1,087,300.00. Following the acquisition, the director directly owned 6,738,817 shares in the company, valued at $732,711,572.41. The trade was a 0.15% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. 0.46% of the stock is currently owned by company insiders.

Abbott Laboratories Stock Performance

NYSE:ABT opened at $112.23 on Wednesday. The stock has a market capitalization of $195.15 billion, a P/E ratio of 30.17, a price-to-earnings-growth ratio of 1.77 and a beta of 0.75. The company has a current ratio of 1.70, a quick ratio of 1.24 and a debt-to-equity ratio of 0.23. Abbott Laboratories has a 1 year low of $105.27 and a 1 year high of $141.23. The firm has a 50 day moving average of $120.24 and a 200-day moving average of $126.70.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.50. Abbott Laboratories had a return on equity of 17.94% and a net margin of 14.72%.The firm had revenue of $11.46 billion during the quarter, compared to analysts’ expectations of $11.80 billion. During the same period last year, the firm posted $1.34 EPS. The business’s revenue was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, sell-side analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 13th. Investors of record on Thursday, January 15th will be issued a $0.63 dividend. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.59. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend is Thursday, January 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 67.74%.

Analysts Set New Price Targets

ABT has been the topic of several analyst reports. Oppenheimer lowered their price target on shares of Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Mizuho increased their price target on shares of Abbott Laboratories from $135.00 to $140.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 14th. The Goldman Sachs Group decreased their price objective on Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating on the stock in a report on Friday, January 23rd. Citigroup dropped their target price on Abbott Laboratories from $155.00 to $140.00 and set a “buy” rating for the company in a report on Friday, January 23rd. Finally, Argus decreased their price target on Abbott Laboratories from $150.00 to $140.00 in a research note on Tuesday, January 27th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $137.05.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.